Infectious diseases

Severe sepsis / septic shock – AB103 peptide, in advanced pre-clinical R&D, was found effective in reducing symptoms of sepsis and toxic shock in mouse models: Gram-positive sepsis, Gram-negative sepsis and superantigen lethality. GMP production and GLP Tox/PK studies have been completed, with AB103 presenting an excellent safety profile.

Avian Influenza - AB103 peptide has demonstrated the ability to completely prevent mortality of Avian Influenza in a mouse model, when co-administered with a neuraminidase inhibitor as antiviral agent.

Toxic shock (Biodefense) - AB103 peptide is in advanced pre-clinical R&D, having demonstrated the ability to protect and rescue mice from lethal toxic shock and protect pigs from intoxication in a quantitative model of incapacitation.

Autoimmune diseases

Several peptide modulators of co-stimulation have demonstrated, using mouse models, significant reduction of symptoms in DTH, Experimental Autoimmune Encephalomyelitis (EAE), and Collagen-Induced Arthritis (CIA). In a rat model of Adjuvant Arthritis, these peptides significantly reduced symptoms even weeks after treatment was stopped, with no rebound of disease.